Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.43 CAD | 0.00% | 0.00% | -12.24% |
Mar. 13 | Crescita Therapeutics Reports Q4 Net Loss of $0.01 Per Share | MT |
Mar. 13 | Tranche Update on Crescita Therapeutics Inc.'s Equity Buyback Plan announced on August 29, 2023. | CI |
Sales 2022 | 23.52M 17.11M | Sales 2023 | 17.52M 12.74M | Capitalization | 9.79M 7.12M |
---|---|---|---|---|---|
Net income 2022 | - 0 | Net income 2023 | -1M -727K | EV / Sales 2022 | 0.29 x |
Net cash position 2022 | 6.7M 4.87M | Net cash position 2023 | 8.13M 5.92M | EV / Sales 2023 | 0.09 x |
P/E ratio 2022 |
16.5
x | P/E ratio 2023 |
-4.9
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 89.65% |
1 month | -2.27% | ||
3 months | -10.42% | ||
6 months | -29.51% | ||
Current year | -12.24% |
Managers | Title | Age | Since |
---|---|---|---|
Serge Verreault
CEO | Chief Executive Officer | - | - |
Jose DaRocha
DFI | Director of Finance/CFO | - | 17-08-31 |
Daniel Chicoine
CHM | Chairman | 70 | 16-02-29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | - | 16-02-29 | |
Daniel Chicoine
CHM | Chairman | 70 | 16-02-29 |
John London
BRD | Director/Board Member | - | 16-02-29 |
1st Jan change | Capi. | |
---|---|---|
-12.24% | 6.13M | |
+33.43% | 690B | |
+26.43% | 546B | |
-5.12% | 358B | |
+19.59% | 323B | |
+4.89% | 287B | |
+14.32% | 235B | |
+5.79% | 199B | |
-9.49% | 195B | |
+4.26% | 161B |
- Stock Market
- Equities
- CTX Stock